一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Recent Results in Cancer Research >>article

Recent Results in Cancer Research

Download PDF

Axitinib (AG-013736).

Published:1 January 2010 DOI: 10.1007/978-3-642-01222-8_3 PMID: 20072829
Ronan Joseph Kelly, Olivier Rixe

Abstract

The vascular endothelial growth factor (VEGF)/VEGF receptor tyrosine kinase (RTK) signaling pathway plays a pivotal role in tumor angiogenesis. Neovascularization promotes increased tumor cell proliferation, survival and metasasis. Many antiangiogenic agents including multi-RTK inhibitors are either approved or are undergoing testing in clinical trials. Axitinib is a potent and selective inhibitor of VEGF RTK 1, 2, and 3. This chapter discusses the stucture of axitinib as well as its toxicities and drug interactions. Important preclinical and clinical data for axitinib are presented including findings from phase II studies in many tumor types including malignant melanoma and renal, pancreatic, thyroid, breast, lung and colorectal carcinomas. Ongoing phase III studies in pancreatic and metastatic renal cell carcinoma will ultimately define the therapeutic role of this targeted agent.

Substances (4)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Axitinib 319460-85-0 C22H18N4OS 511 suppliers $7.00-$1764.00
HUMAN VEGF165 127464-60-2 NULL 223 suppliers $98.40-$908.00
VEGF Receptor 2 13 suppliers Inquiry
RTK TOTAL 7-PLEX 4 suppliers Inquiry

Similar articles

IF:4.6

Clinical pharmacology of axitinib.

Clinical Pharmacokinetics Ying Chen, Michael A Tortorici,etc Published: 1 September 2013
四会市| 南丹县| 太仆寺旗| 桃源县| 桃源县| 德州市| 乌审旗| 当雄县| 股票| 桃源县| 汽车| 郸城县| 甘泉县| 娱乐| 瑞安市| 莒南县| 井陉县| 依安县| 闽侯县| 双流县| 凌云县| 奉新县| 马鞍山市| 桦南县| 侯马市| 香港 | 怀远县| 天全县| 兴安县| 新化县| 浮梁县| 全椒县| 江川县| 全南县| 攀枝花市| 白银市| 嘉禾县| 舟山市| 景东| 扶风县| 大连市|